EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC

View source ↗

Summary

Trodelvy (sacituzumab govitecan) has been authorised by the EMA for breast cancer indications including triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Triple Negative Breast Neoplasms

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Triple Negative Breast Neoplasms. MAH: Gilead Sciences Ireland UC. Decision date: 23/07/2026